About Medtronic DBS Patient Assessment
The DBS Patient Assessment
New to the DBS Patient Assessment?
This tool was developed to optimize the referral process
for Parkinson’s patients who may benefit from Deep Brain Stimulation (DBS) therapy.
Built on the expertise of 82 international DBS neurologists and neurosurgeons, and validated through the
RAND/UCLA methodology, the tool provides clear, evidence-based guidance to help general and referral
neurologists identify appropriate patients for evaluation at a DBS expert center.
At the surgical center, specialists will determine final eligibility for DBS therapy. By streamlining
referrals and supporting decision-making, the DBS Patient Assessment enhances efficiency and ensures that
more patients have timely access to advanced treatment options.
Our therapies improve the lives of more than 2 people every second1
Medtronic was founded in 1949 as a medical equipment repair shop by Earl Bakken and his brother-in-law,
Palmer Hermundslie.
Did these two men set out to change medical technology and the lives of millions of people? No. But they
did have a deep moral purpose and an inner drive to use their scientific knowledge and entrepreneurial
skills to help others.
That spirit — combined with our founders' personal integrity and passion — became our guiding philosophy
and, ultimately, the Medtronic Mission.
Our first life-changing therapy — a wearable, battery-powered cardiac pacemaker — was the foundation for
many more Medtronic therapies that use our electrical stimulation expertise to improve the lives of
millions of people.
With an eye on reducing healthcare costs through innovation, Medtronic therapies are helping to alleviate
pain, restore health, and extend the life of patients worldwide. Medtronic also goes beyond therapies and
devices, using its technology and expertise to help physicians provide better, more efficient
care.
In 1987, Medtronic partnered with Professor Benabid and Professor Pollak to pioneer Deep Brain
Stimulation, giving the company more than 30 years of experience and clinical research in this
life-changing therapy.
1: Medtronic FY25 Impact report